165 related articles for article (PubMed ID: 24684645)
1. Budget impact analysis of antiepileptic drugs for Lennox-Gastaut syndrome.
Skornicki M; Clements KM; O'Sullivan AK
J Manag Care Spec Pharm; 2014 Apr; 20(4):400-6. PubMed ID: 24684645
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of antiepileptic drugs in the treatment of Lennox-Gastaut syndrome.
Clements KM; Skornicki M; O'Sullivan AK
Epilepsy Behav; 2013 Oct; 29(1):184-9. PubMed ID: 23973644
[TBL] [Abstract][Full Text] [Related]
3. Stable dosages of clobazam for Lennox-Gastaut syndrome are associated with sustained drop-seizure and total-seizure improvements over 3 years.
Conry JA; Ng YT; Kernitsky L; Mitchell WG; Veidemanis R; Drummond R; Isojarvi J; Lee D; Paolicchi JM;
Epilepsia; 2014 Apr; 55(4):558-67. PubMed ID: 24580023
[TBL] [Abstract][Full Text] [Related]
4. Clobazam is efficacious for patients across the spectrum of disease severity of Lennox-Gastaut syndrome: post hoc analyses of clinical trial results by baseline seizure-frequency quartiles and VNS experience.
Wheless JW; Isojarvi J; Lee D; Drummond R; Benbadis SR
Epilepsy Behav; 2014 Dec; 41():47-52. PubMed ID: 25282105
[TBL] [Abstract][Full Text] [Related]
5. Anti-seizure medications for Lennox-Gastaut syndrome.
Brigo F; Jones K; Eltze C; Matricardi S
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD003277. PubMed ID: 33825230
[TBL] [Abstract][Full Text] [Related]
6. Indirect comparison of clobazam and other therapies for Lennox-Gastaut syndrome.
Cramer JA; Sapin C; François C
Acta Neurol Scand; 2013 Aug; 128(2):91-9. PubMed ID: 23410109
[TBL] [Abstract][Full Text] [Related]
7. The cost effectiveness of rufinamide in the treatment of Lennox-Gastaut syndrome in the UK.
Benedict A; Verdian L; Maclaine G
Pharmacoeconomics; 2010; 28(3):185-99. PubMed ID: 20151724
[TBL] [Abstract][Full Text] [Related]
8. Use and cost comparison of clobazam to other antiepileptic drugs for treatment of Lennox-Gastaut syndrome.
François C; Stern JM; Ogbonnaya A; Lokhandwala T; Landsman-Blumberg P; Duhig A; Shen V; Tan R
J Mark Access Health Policy; 2017; 5(1):1318691. PubMed ID: 28740620
[No Abstract] [Full Text] [Related]
9. Optimizing clobazam treatment in patients with Lennox-Gastaut syndrome.
Isojarvi J; Gidal BE; Chung S; Wechsler RT
Epilepsy Behav; 2018 Jan; 78():149-154. PubMed ID: 29202277
[TBL] [Abstract][Full Text] [Related]
10. Rufinamide: a pharmacoeconomic profile of its use as adjunctive therapy in Lennox-Gastaut syndrome.
McCormack PL
Pharmacoeconomics; 2012 Mar; 30(3):247-56. PubMed ID: 22332960
[TBL] [Abstract][Full Text] [Related]
11. Burden of illness in patients with possible Lennox-Gastaut syndrome: A retrospective claims-based study.
Reaven NL; Funk SE; Montouris GD; Saurer TB; Story TJ
Epilepsy Behav; 2018 Nov; 88():66-73. PubMed ID: 30241056
[TBL] [Abstract][Full Text] [Related]
12. Deconstructing tolerance with clobazam: Post hoc analyses from an open-label extension study.
Gidal BE; Wechsler RT; Sankar R; Montouris GD; White HS; Cloyd JC; Kane MC; Peng G; Tworek DM; Shen V; Isojarvi J
Neurology; 2016 Oct; 87(17):1806-1812. PubMed ID: 27683846
[TBL] [Abstract][Full Text] [Related]
13. Expert opinion: Proposed diagnostic and treatment algorithms for Lennox-Gastaut syndrome in adult patients.
Montouris G; Aboumatar S; Burdette D; Kothare S; Kuzniecky R; Rosenfeld W; Chung S
Epilepsy Behav; 2020 Sep; 110():107146. PubMed ID: 32563898
[TBL] [Abstract][Full Text] [Related]
14. Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome.
Ng YT; Conry JA; Drummond R; Stolle J; Weinberg MA;
Neurology; 2011 Oct; 77(15):1473-81. PubMed ID: 21956725
[TBL] [Abstract][Full Text] [Related]
15. Current and emerging pharmacotherapy for the treatment of Lennox-Gastaut syndrome.
Besag FMC; Vasey MJ; Chin RFM
Expert Opin Pharmacother; 2023; 24(11):1249-1268. PubMed ID: 37212330
[TBL] [Abstract][Full Text] [Related]
16. Clobazam and Aggression-Related Adverse Events in Pediatric Patients With Lennox-Gastaut Syndrome.
Paolicchi JM; Ross G; Lee D; Drummond R; Isojarvi J
Pediatr Neurol; 2015 Oct; 53(4):338-42. PubMed ID: 26245776
[TBL] [Abstract][Full Text] [Related]
17. Clobazam-treated patients with Lennox-Gastaut syndrome experienced fewer seizure-related injuries than placebo patients during trial OV-1012.
Isojarvi J; Lee D; Peng G; Sperling MR
Epilepsia; 2016 Jun; 57(6):e113-6. PubMed ID: 27145465
[TBL] [Abstract][Full Text] [Related]
18. Clobazam is equally safe and efficacious for seizures associated with Lennox-Gastaut syndrome across different age groups: Post hoc analyses of short- and long-term clinical trial results.
Ng YT; Conry J; Mitchell WG; Buchhalter J; Isojarvi J; Lee D; Drummond R; Chung S
Epilepsy Behav; 2015 May; 46():221-6. PubMed ID: 25940107
[TBL] [Abstract][Full Text] [Related]
19. Rufinamide for the treatment of Lennox-Gastaut syndrome: evidence from clinical trials and clinical practice.
Striano P; McMurray R; Santamarina E; Falip M
Epileptic Disord; 2018 Feb; 20(1):13-29. PubMed ID: 29313492
[TBL] [Abstract][Full Text] [Related]
20. Retrospective chart review study of use of cannabidiol (CBD) independent of concomitant clobazam use in patients with Lennox-Gastaut syndrome or Dravet syndrome.
Nabbout R; Arzimanoglou A; Auvin S; Berquin P; Desurkar A; Fuller D; Nortvedt C; Pulitano P; Rosati A; Soto V; Villanueva V; Cross JH
Seizure; 2023 Aug; 110():78-85. PubMed ID: 37331197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
